Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer
Abstract Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical factors predictive of severe to end-stage chronic ki...
Збережено в:
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2024-02-01
|
| Серія: | Radiation Oncology |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s13014-024-02413-w |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|